藥師幫2023年度業績：總GMV達469億元同增24%，經調淨利潤轉正達1.3億元
中國最大的院外醫藥產業數字化服務平台藥師幫(9885.HK)發佈2023年度業績報吿。報吿期內，總GMV達469.1億元，同比增長24%；營業收入169.7億元，同比增長18.9%；毛利額17.4億元，同比增長21.3%；年度經調整後淨利潤全面轉正達1.3億元，經營性現金流入超4.5億元。
其中，“平台+自營”業務的協同效應進一步放大。報吿顯示，藥師幫平台上游商家達8100家，可售SKU超360萬個，其中醫療健康產品SKU同比增長超過50%。 自營業務供應商達到10000家，月均SKU數約34.7萬個，同比增長37.6%；自營業務平均可在3小時內完成出庫，存貨週轉天數為30天，優於行業平均水平。基於算法及公司在自營業務和平台業務交易中積累的洞見，公司在2023年度持續拓展廠牌首推業務。報吿期內，藥師幫與500家藥企合作推廣，過千萬人民幣銷售額廠牌超10家，超千萬人民幣銷售額品種15個。自有品牌“樂藥師”，完成超60個品種的現貨交付，銷售金額過千萬品種5個，覆蓋超過20萬個下游藥店診所。
在保持業績穩健增長的同時，公司規模優勢也在持續擴大。截至2023年12月31日，藥師幫累計註冊買家數超過65萬家，其中藥店約40.1萬家，基層療機構約24.6萬家；月均活躍買家數達36.7萬家，同比增長19%；月均付費買家數達34.3萬家，同比增長21.1%；月均付費率由91.7%同比上升至93.3%，且每個付費買家月均訂單數由去年同期的27.3單上升8.7%至29.6單。而營銷及銷售費用佔收入比重下降至8.2%。相較2022年同期，藥師幫平台業務補貼率從0.7%降至0.6%，平台業務佣金率從3.1%增至3.2%。
根據弗若斯特沙利文的資料，中國院外數字化醫藥流通服務市場的市場規模預計於2027年將達人民幣3,583億元，年複合增長率為14.7%，對整體院外醫藥流通市場的滲透率將達35.4%，呈現出廣闊的發展空間。隨着互聯網醫療的快速發展和政策支持的不斷加大，市場潛力還將持續釋放。
得益於國內廣闊的行業覆蓋，疊加良好的數字化能力，藥師幫能夠以更高效的方式擴大用户羣體、提升流通效率、增加變現機會，推動業務持續增長。利用數字化生態的網絡效應，2024年，藥師幫將採取更加主動的經營策略，通過加碼數字化、夯實服務力等措施，深化產業鏈上下游合作，不斷升級自身生態系統，以迎接市場機會與挑戰。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
